Product Name: FLT3 (Ab 591) Antibody
Species Reactivity: Human
Tested Applications: IF, WB
Applications: Western Blot: 1:500~1:1000, Immunofluorescence: 1:100~1:200
User Note:
Predicted Molecular Weight: 130, 160 kDa
Immunogen: FLT3 (Ab-591) antibody was raised against a peptide sequence around aa.589~593 (Y-F-Y-V-D) derived from Human FLT3.
Host Species: Rabbit
Purification: Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Physical State: Liquid
CAS NO.: 1223001-51-1
Torin 2
Buffer: Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration: 1 mg/mL
Storage Conditions: Store antibody at -20˚C for up to one year.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: FLK2, STK1, CD135, FLK-2, CDKN6, FLT-3, FLT3, STK-1
Accession NO.: NP_004110.2
Protein Ino: 121114304
Official Symbol: FLT3
Geneid: 2322
Background: FLT3 encodes a class III receptor tyrosine kinase that regulates hematopoiesis. The receptor consists of an extracellular domain composed of five immunoglobulin-like domains, one transmembrane region, and a cytoplasmic kinase domain split into two parts by a kinase-insert domain. The receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.
PubMed ID:http://aac.asm.org/content/41/4/850.abstract
